Search tips
Search criteria 


Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
J Pharm Biomed Anal. Author manuscript; available in PMC 2010 April 28.
Published in final edited form as:
PMCID: PMC2861046

Identification of 4-deoxythreonic acid present in human urine by combining HPLC and NMR techniques


The 1H NMR spectrum of urine exhibits a large number of detectable and quantifiable metabolites and hence urine metabolite profiling is potentially useful for the study of systems biology and the discovery of biomarkers for drug development or clinical applications. While a number of metabolites (50–100) are readily detectable in urine by NMR, a much larger number is potentially available if lower concentration species can be detected unambiguously. Lower concentration metabolites are thought to be more specific to certain disease states and thus it is important to detect these metabolites with certainty. We report the identification of 4-deoxythreonic acid, a relatively low concentration endogenous metabolite that has not been previously identified in the 1H NMR spectrum of human urine. The complimentary use of HPLC and NMR spectroscopy facilitated the unequivocal and non-invasive identification of the molecule in urine which is complicated by extensive peak overlap and multiple, similar resonances from other metabolites such as 3-hydroxybutanoic acid. High-resolution detection and good sensitivity were achieved by the combination of multiple chromatographic fraction collection, sample pre-concentration, and the use of a cryogenically cooled NMR probe.

Keywords: Metabolite, Metabolomics, HPLC-NMR, Urine, TOCSY, 4-deoxythreonic acid

1. Introduction

Nuclear Magnetic Resonance (NMR) has shown high utility in the area of metabolite profiling and metabolomics or metabonomics.12 Metabolite profiling, which involves the combination of high-resolution spectroscopy with multivariate statistical methods, allows the exploration of subtle differences in sample cohorts by detecting multiple metabolites quantitatively and in parallel.36 Identifiable differences in the spectra that can be related to metabolic variance add to the current knowledge of systems biology and may lead to disease detection or prediction, among a number of applications. The process of NMR-based biomarker identification is culminated by peak assignment, a task that is usually challenged by the high complexity of the NMR biofluid spectra.7 The existence of NMR databases has improved the peak assignment process; nevertheless a close examination of these databases suggest that they are often inadequate for a complete and unambiguous assignment, particularly for molecules that are at low abundance.

1H-NMR data is by far the most prevalent in NMR-based metabolomics research because of its high sensitivity arising from the high isotopic abundance of 1H and its large gyromagnetic ratio. However, the molecular complexity of biofluids results in overlapping signals that makes peak assignment difficult. Additionally, urine pH and ion concentration has been shown to affect the chemical shift values of peaks, which can be reduced but not completely eliminated.89 These chemical shift variations may potentially lead to errors in peak assignments; consequently it not uncommon to find incorrect peak assignments in the NMR literature. Despite these limitations, however, human urine has served as the sample of choice for numerous metabolomic investigations owing to its relatively ease of collection, low protein content that results in high resolution NMR spectra, and presence of a large number of metabolites in relatively significant concentrations.10 As an example of the challenges in metabolite identification, consider the assignment of doublets that occur in the range of 1.20 ppm to 1.25 ppm in the 1H-NMR spectrum. The relatively common metabolite 3-hydroxybutanoic acid is known to have a CH3 (doublet) resonance in that region. However a detailed examination of this peak using selective TOCSY showed read peaks that were not consistent with 3-hydroxybutyrate. The standard approach for identifying small molecule metabolites includes the use of 1D 1H and 13C as well as several 2D NMR experiments. However, this approach is challenging for the identification of unknown species in complex mixtures such as biofluids because of the degree of spectral overlap. Selective TOCSY can be used to improve the situation by minimizing sample complexity that leads to improved detection.1112 However, this approach is typically not sufficient to make an unambiguous assignment of an unknown species.

Owing to the previously outlined issues, a logical choice for simplifying a complex biological matrix such as urine, while concomitantly improving the concentration of analytes for NMR analysis, is chromatographic fractionation. LC-NMR methods have been utilized in several metabolomics studies in which the power of the two complimentary techniques has allowed for the rapid characterization of both xenobiotic and endogenous metabolites.1316

We have previously demonstrated how hyphenated LC-NMR systems can be used to isolate drug metabolites prior to NMR acquisition with concomitant signal enhancement of up to 90-fold.1718 In this work; we apply the methods of HPLC-NMR to identify a previously unknown endogenous metabolite, 4-deoxythreonic acid. Selective TOCSY and two-dimensional experiments were utilized to elucidate the structure of the metabolite ab initio. Structural confirmation was obtained by synthesis of the compound followed by spiking experiments which gave a positive match with the peak present in the human urine fraction. The use of a chromatogram-resolved NMR approach is advantageous because it reduces the complexity of biofluids leading to the ability to detect low concentration metabolites unambiguously.

2. Experimental Section

2.1 Reagents

Deuterium oxide (D2O, 99.9%) was obtained from Cambridge Isotope Laboratories Inc. (Andover, MA). HPLC-grade acetonitrile (ACN, 99.8%), methanol (MeOH, 99.9%), acetone, butan-2-ol and formic acid (88%) were purchased from Mallinckrodt Baker, Inc. (St Louis, MO) Sodium azide was obtained from Fisher Scientific (Pittsburgh, PA). Crotonic acid, N-methylmorpholine-N-oxidedihydrate, sodium dithionite, ethyl acetate, sodium 3-trimethylsilyl (2, 2, 3, 3-2H4)-1-propionate (TSP), osmium tetraoxide (2.5%) were obtained from Sigma Aldrich (St Louis, MO). All compounds were used without additional purification. Deionized water was obtained from an EASY pure II UV water purification system (Barnstead International, Dubuque, IA).

2.2 Urine collection and purification

Urine samples were collected from three healthy donors. Sodium azide (0.1%, w/v) was added to the freshly collected urine to prevent bacterial growth, and samples were then purified by centrifugation using Centriprep filters (cat. no. 4321, Millipore, Bedford, MA). The following standard procedure was used: urine samples were pipetted into two filters (15 ml each); the filters were spun at 4000 rpm for 30 min, and the supernatant was then collected. Purified samples were stored at −80 °C. Urine samples were lyophilized to concentrate them by a factor of 6 prior to HPLC separations. All urine samples were collected and processed according to an approved IRB protocol at Purdue University.

2.3 HPLC separation and fractionation

The HPLC system was composed of an LC-10AS Pump and SCL-10A System Controller (Shimadzu Corporation, Kyoto, Japan), 6-port injection valve (Rheodyne, CA, USA), and SPD-10A UV-vis Detector (Shimadzu Corporation, Kyoto, Japan). Fused silica tubes, 125 μm ID, and stainless steel fittings were used as the transfer lines and connectors, respectively (Upchurch Scientific, WA). The HPLC system was operated using Shimadzu EZStart 7.2 software. The analytical separation was performed on a 150 mm × 4.6 mm Hypersil Gold AQ C18 column and a 250 mm × 2.1 mm Beta Basic-18 (Thermo Electron Corporation, MA) connected in series in order to offer a higher loading capacity. The following gradient elution protocol was utilized: 60% (H2O, 0.1 % formic acid)/40% CH3OH (25 min) [implies] linear ramp to 20% (H2O, 0.1 % formic acid)/80% CH3OH (55 min) [implies] 95% (H2O, 0.1 % formic acid) 5% CH3OH (10 min). The flow rate was 250 μL/min and a 500 μl injection volume was used. Fractions were collected over 2 min time intervals using a Gilson FC-203B fraction collector. Collected fractions were dried with N2 gas.

2.4 1-D NMR Spectroscopy

The samples for NMR analysis were prepared by reconstituting the dried HPLC fractions in 550μL of phosphate buffer in D2O. All samples were prepared in 5-mm tubes with 50 μM TSP for locking and chemical shift referencing, respectively. NMR spectra were obtained on a Bruker Avance DRX 500 MHz spectrometer, equipped with a 5mm TXI triple resonance Z-gradient cryoprobe. All spectra were acquired at room temperature, and were referenced to the TSP methyl peak at 0.00 ppm. Proton spectra were acquired using a 1D NOESY pulse sequence incorporating presaturation for residual water suppression during the relaxation delay and mixing times. The relaxation delay and mixing times were set to 2 s and 300 ms, respectively, with a presaturation power of 50 dB in order to achieve complete water peak saturation. 64 FID transients were averaged; resulting in a total acquisition time of 5.15 min. Selective TOCSY experiments utilized the standard pulse sequence obtained from the pulse program library of Bruker XWINNMR. This consisted of a hard 90° pulse—z—gradient—selective 180° pulse—z—gradient train to achieve selective excitation of the target peak at 1.23 ppm, followed by a DIPSI-2 spin lock. Gaussian-shaped pulsed z-field gradients were 2 ms in duration. The duration of the shaped pulse was 50 ms and the TOCSY mixing time was 60 ms. A total of 256, 16K point FID transients were averaged in each selective TOCSY experiment, resulting in an acquisition time of 45.41 min. Line broadening of 0.10 Hz was used in processing the data.

2.5 2-D NMR Spectroscopy

Following the identification of the fraction of interest using 1-D proton NMR, several two dimensional experiments were performed, including 1H-1H double quantum filtered correlation spectroscopy (DQF-COSY), 1H-1H total correlation spectroscopy (TOCSY), sensitivity enhanced heteronuclear and multiplicity edited 1H-13C heteronuclear single quantum correlation (edited HSQC) and 1H-13C gradient enhanced heteronuclear multiple bond correlation (HMBC) experiments. For the DQF-COSY experiments, a sweep width of 5483 Hz was used in both dimensions, 512 t1 increments were acquired and were zero filled to twice to make 2048 spectral data points in each dimension. The number of transients per t1 increment was 32, and the relaxation delay was 3 s. Phase sensitive data were obtained using the TPPI method. 2D-TOCSY data were obtained in echo-antiecho mode. A spectral width of 5485 Hz was used in both dimensions. The number of t1 increments was 512, and 32 transients, each of 2048 data points was acquired per t1 increment. Both 1H-13C multiplicity edited HSQC and HMBC experiments were performed with spectral widths of 5483 Hz and 29,000 Hz in the 1H and 13C dimensions, respectively. The number of t1 increments was 256 and 128 transients (each 2048 data points) were acquired per t1 increment. The recycle delay was set to 1.5 s. Phase-sensitive data for the edited HSQC experiment was obtained using echo-antiecho mode. For the HMBC experiment, NMR data were obtained in magnitude mode without proton decoupling in the t2 dimension. The resulting NMR data were zero filled to 1024 points in the t1 dimension and double Fourier transformed after multiplying by a squared sine-bell window function shifted by π/2 along both dimensions.

2.5 Synthesis of 4-deoxyerythronic acid and 4-deoxythreonic acid

The target compounds were synthesized following the methods developed by Armstrong et al.21 30% hydrogen peroxide (1.4 equiv) was added to a solution of crotonic acid (0.1 g) and 90% formic acid (500 μL). The mixture was stirred at 70 °C for 3 hrs and then left overnight at room temperature. The solution was then concentrated under reduced pressure. 4-deoxythreonic acid was synthesized by the addition of an aqueous solution of osmium tetraoxide (2.5%, 3 μL) to a solution of crotonic acid (0.1 g) and N-methylmorpholine N-oxide dihydrate (0.2 g) in a mixture of water (400 μL), acetone (600 μL), and butan-2-ol (100 μL). The mixture was stirred overnight. Sodium dithionite (0.02 g) was added, stirred for 2 min and extracted with diethyl ether (2 × 20 ml). The ethereal extract was concentrated under reduced pressure. 19

3. Results and discussion

A typical urine spectrum can be seen in Figure 1, with a number of doublets apparent in the 1.0 to 1.5 ppm region, as indicated in the expanded region. Of particular interest is the peak at 1.23 ppm, which is in the region where 3-hydroxybutyrate has been observed. However, a selective TOCSY experiment, using an excitation centered at 1.23 ppm (Figure 2A) indicates that the species of interest is not 3-hydroxybutyrate shown in Figure 2B. In order to identify this metabolite, it was necessary to fractionate and concentrate the urine sample prior to NMR analysis.

Figure 1
NMR spectra of a normal human urine. Insert shows the expanded 1.1–1.5 ppm region where a number of doublets appear.
Figure 2
A) Selective TOCSY spectrum of region of interest from whole urine showing doublet at 1.23 ppm and a number of other doublets. B) Selective TOCSY spectrum of 3-hydroxybutanoic acid.

Figure 3 shows a chromatogram of urine separated by reverse-phase chromatography. Even under optimum conditions it was impossible to obtain baseline separation of the region that extends from 12 to almost 40 min. In order to determine the region of interest, we collected eight urine fractions using 10 min time intervals corresponding to the entire span of the chromatogram. This procedure was repeated five times using an injection volume of 500 μL each. These fractions were dried and reconstituted in pH 7.0 phosphate buffer. 1H NMR spectra were collected for the individual fractions in order to identify the region that contained the metabolite of interest. From this process it was determined that the first fraction contained the metabolite of interest. The chromatography was then repeated, but this time 2 min collection intervals were used to sub divide the first fraction. A total of 4 sub-fractions were collected, from which it was again determined that the second sub-fraction contained the highest concentration of the unknown metabolite of interest. Even though highly concentrated metabolites such as lactate and alanine co-eluted with the analyte of interest, the NMR spectrum of the fraction of interest (shown in Figure 4A) was much simpler than the original (whole) urine spectrum of Figure 1, and resulted in an improved spectral resolution. Consequently, all subsequent NMR experiments were performed using this sub-fraction.

Figure 3
Chromatogram of urine separation under reverse-phase conditions.
Figure 4
A) 1-D 1H-NMR spectrum of the urine fraction of interest showing the expanded view of the region containing the unidentified peaks of interest. B) Selective TOCSY spectrum of the molecule of interest showing all read peaks. The excitation was centered ...

A selective TOCSY pulse sequence was utilized to irradiate the doublet at 1.23 ppm in order to determine the corresponding proton signals that are associated with the unknown molecule. It can be observed from Figure 4B that the selective TOCSY read peaks are comprised of a doublet at 3.85 ppm and a multiplet at 4.06 ppm. This result confirmed that indeed the peak of interest was not that of 3-hydroxybutanoic acid, which has a doublet at 1.20 ppm and two multiplets at 2.31 ppm and 4.13 ppm.

3.1 Structure Elucidation

A CH-CH-CH3 fragment of the metabolite was tentatively identified by tracing the cross peak positions along both frequency dimensions in the DQF-COSY and TOCSY spectra, taking into account the signals in the 1D 1H NMR spectra (See Supplementary Figure S1). Multiplicity edited HSQC and HMBC spectra facilitated the assignment of the carbon chemical shifts for the directly attached protons as well as the carbon multiplicity (See Supplementary Figure S2). The three proton attached carbons (see Figure 6 and Table 1) were identified in the HSQC spectrum based on the corresponding proton chemical shifts obtained from the analysis of the DQF-COSY spectrum. The sign of all the three cross peaks in the HSQC spectrum was negative thus confirming that all the protonated carbons belong to CH or CH3 groups. The long-range couplings among CH and CH3 groups observed in the HMBC spectrum matched with the CH-CH-CH3 moiety of the metabolites. From these assignments, the tentative proton assignments of the DQF-COSY spectra were confirmed. However the carboxylic acid carbons were not readily observable in both HSQC and HMBC spectra. This is likely due to issues arising from the relatively low concentration of the metabolite. Nevertheless, based on the observable signals, the molecule was predicted to be 2, 3-dihyroxybutanoic acid, although the stereochemistry was not known a priori.

Figure 6
A) Metabolic pathway showing the production of the two possible isomers of 2, 3 dihydroxybutanoic acid (4-deoxythreonic acid and 4-deoxyerythronic acid). The latter was not observed by NMR in the urine samples.
Table 1
1H and 13C chemical shift assignments for the two isomers. NMR spectra were referenced to the TSP peak at 0.00 pm for proton and carbon. All samples were measured at biological pH 7.0.

3.2 Structural confirmation by spiking of the synthesized molecule

In order to confirm our findings, we used two previously published protocols to synthesize the predicted molecule.19 The 1D 1H-NMR of both molecules showed an interestingly close similarity for the two possible diastereomers for this molecule in terms of the distribution of the signals. We could use NMR to differentiate the two molecules owing to the differences in chemical shifts and scalar coupling constants from the 1D 1H NMR spectra. Other approaches would have required tedious and possibly time-consuming chromatographic separation in order to resolve the two molecules.2021

To demonstrate that we were actually observing 4-deoxythreonic acid and not the 4-deoxyerythronic acid, the other possible diastereomer in the urine fraction sample, a selective TOCSY was performed by irradiating the doublet at 1.23 ppm before and after spiking urine fraction with an aliquot of the synthesized product. As can be seen in Figure 5B, the selective TOCSY spectrum showed a close similarity for the read peak spectrum with that of Figure 4B, which shows the spectrum before spiking, and hence provides strong structural confirmation. These results were further confirmed by performing DQF-COSY and HMBC experiments for both isomeric synthetic products. The results are summarized in Table 1, in which we provide a complete list of 1H and 13C chemical shifts for both metabolites. We believe this is the first report of the complete NMR chemical shifts of this metabolite in human urine.

Figure 5
A) 1-D 1H-NMR spectrum of urine fraction spiked with synthesized 4-deoxythreonic acid and an expanded view showing a difference in the intensity of the peak of interest as compared to Figure 3A. B) Selective TOCSY spectrum (excitation centered at 1.23 ...

The two molecules, 4-deoxythreonic acid and 4-deoxyerythronic acid, have been previously reported as potential biomarkers for type 1 diabetes using hyphenated GC-MS techniques. 2022 A pathway for the likely production of these two metabolites has been postulated using an animal model, in which it was suggested that these molecules were products of L-threonine metabolism. L-threonine is a ketogenic amino acid, hence its catabolism yields products that are able to enter into energy producing metabolic pathways such as the Krebs cycle.23 Threonine has three major routes of degradation, two of which produce acetyl-COA that is a major source of carbon atoms in the Krebs cycle, while the third route produces a precursor for the formation of isoleucine.23 Despite the knowledge of these metabolic routes, there exists the possibility of another metabolic pathway involving threonine as its source that is expected to produce 4-deoxythreonic acid.22 This involves a deamination step that is catalyzed by the enzyme threonine deaminase which results in the production of 2-keto-3-hydroxybutytrate followed by the action of a reductase to form 4-deoxythreonic acid or 4-deoxyerythronic acid. We did not observe signals arising from 4-deoxyerythronic in our data, however. This could be due to a stereo-specificity of this pathway in human metabolism. Alternatively, perhaps its production in a relatively healthy human subject results in quantities that are well below NMR detectable levels.

In order to demonstrate that the identified metabolite was a normal and endogenous human urinary metabolite, urine was obtained from two additional donors who have different dietary patterns. The 1D 1H NMR spectrum of both samples showed the presence of the 4-deoxythreonic acid and the absence of the other diastereomer as can be seen in Figure 7A and B. A broader study would be needed to establish the relationship between the up-regulation of 4-deoxythreonic acid and diabetes. Additionally, owing to the issues that were encountered during the chromatographic method development process, we recommend that other chromatographic methods such as hydrophilic interaction chromatography (HILIC) be investigated, since it is expected to offer better separation of the highly polar metabolites that are normally found in urine samples. 2425 We plan to investigate this approach in future metabolomic investigations using HPLC-NMR.

Figure 7
1H-NMR spectrum of urine obtained from A) donor 1 and B) donor 2, respectively. Spectra were obtained before (lower) and after (upper) spiking with 4-deoxythreonic acid for each donor.


We have successfully utilized a chromatogram resolved NMR approach for the identification of a previously unidentified human urine metabolite, 4-deoxythreonic acid. The use of this approach further enhances the 1H NMR spectral resolution of normal human urine. 4-deoxythreonic acid appears to be a component in normal human urine; however, 4-deoxyerythronic acid is either absent or present in very low concentration. The approach used here may be further improved by the use of HILIC columns that are expected to provide better separation of polar metabolites. The identification of 4-deoxythreonic acid is expected to provide the basis for further studies involving larger sample sets in order to establish its possible role as a disease marker.

Supplementary Material


The authors gratefully acknowledge the NIH (1R01GM085291-01) for financial support, and thank the Amy Facility staff at Purdue for their technical assistance.

Financial Support

This work was supported by the NIH (1R01GM085291-01).


1. Bales JRPJ, Nicholson JK, Timbrell JA. Clin Chem. 1984;30(10):1631–1636. [PubMed]
2. Nagana Gowda GA, Zhang S, Haiwei G, Asiago V, Shanaiah N, Raftery D. Expert Rev Mol Diagn. 2008;8:617–633. [PMC free article] [PubMed]
3. Lindon JC, Holmes E, Nicholson JK. Prog Nucl Magn Reson Spectrosc. 2001;39:1–40.
4. Lanza IR, Zhang S, Karakelides H, Raftery D, Nair S. Diabetes. 2008;57:A698–A699.
5. Zhang S, Gowda GAN, Asiago V, Shanaiah N, Barbas C, Raftery D. Anal Biochem. 2008;383:76–84. [PMC free article] [PubMed]
6. Lindon JC, Holmes E, Nicholson JK. Prog Nucl Magn Reson Spectrosc. 2004;45:109–143.
7. Pan Z, Gu H, Talaty N, Chen H, Shanaiah N, Hainline BE, Cooks RG, Raftery D. Anal Bioanal Chem. 2007;387(2):539–549. [PubMed]
8. Asiago VM, Gowda Nagana GA, Zhang S, Shanaiah N, Clark J, Raftery D. Metabolomics. 2008;4:328–336.
9. Laurisden M, Hansen SH, Jaroszewski JW, Cornett C. Anal Chem. 2007;79:1181–1186. [PubMed]
10. Saude EJ, Adamko D, Rowe BH, Marrie T, Sykes BD. Metabolomics. 2007;3:439–451.
11. Sandusky P, Raftery D. Anal Chem. 2005;77:2455–2463. [PubMed]
12. Sandusky P, Raftery D. Anal Chem. 2005;77:7717–7723. [PubMed]
13. Nicholls AW, Farrant RD, Shockor JP, Unger SE, Wilson ID, Lindon JC, Nicholson JK. J Pharm Biomed Anal. 1997;15:901–910. [PubMed]
14. Graça G, Duarte IF, Goodfellow BJ, Carreira IM, Couciero AB, Domingiues M, Spraul M, Tseng L, Gil AM. Anal Chem. 2008;80:6085–6092. [PubMed]
15. Lenz EM, Williams RE, Sidaway J, Smith BW, Plumb RS, Johnson KA, Rainville P, Shockcor J, Stumpf CL, Granger JH, Wilson ID. J Pharm Biomed Anal. 2007;44:845–852. [PubMed]
16. Shockcor JP, Unger SE, Wilson ID, Foxall PJD, Nicholson JK, Lindon JC. Anal Chem. 1996;68:4431–4435. [PubMed]
17. Djukovic D, Appiah-Amponsah E, Shanaiah N, Nagana Gowda GA, Henry I, Everly M, Tobias B, Raftery M. J Pharm Biomed Anal. 2008;47:328–334. [PubMed]
18. Djukovic D, Liu S, Henry I, Tobias B, Raftery D. Anal Chem. 2006;78:7154–7160. [PMC free article] [PubMed]
19. Armstrong FB, Lipscomb EL, Crout DHG, Morgan PJ. J Chem Soc. 1985;1:691–696.
20. Thompson JA, Markey SP, Fennessey PV. Clin Chem. 1975;21:1892–1898. [PubMed]
21. Ballèvre O, Prugnaud J, Houlier ML, Arnal M. Anal Biochem. 1991;193:212–219. [PubMed]
22. Kassel DB, Martin M, Schall W, Sweeley CC. Biomed Mass Spectrom. 1986;13:535–540. [PubMed]
23. Horton RH, Moran LA, Ochs RS, Rawn DJ, Scrimgeour GK. Principles of Biochemistry. 3. Prentice-Hall Inc; Upper Saddle River, New Jersey: 2002.
24. Kind T, Tolstikov V, Fiehn O, Weiss RH. Anal Biochm. 2007;363:185–195. [PubMed]
25. Godejohann M. J Chrom A. 2007;1156:87–93. [PubMed]
26. Nelson DL, Cox MM. Lehninger, Principles of Biochemistry. 3. Worth Publishing; New York: 2000.
27. Nagana Gowda GA. Chem Phys Letts. 2002;353:49–54.